Identification of Combinations of Approved Drugs With Synergistic Activity Against Ebola Virus in Cell Cultures.
暂无分享,去创建一个
Paul Shinn | Rajarshi Guha | Elena Postnikova | Julie Dyall | Ian Crozier | Carleen Klumpp-Thomas | Crystal McKnight | Tim Mierzwa | Michael R Holbrook | Lisa E Hensley | Peter B Jahrling | P. Shinn | R. Guha | G. Olinger | E. Postnikova | P. Jahrling | Pamela J. Glass | L. Hensley | E. Nelson | Lisa Evans DeWald | L. Johansen | Patrick J. Morris | Craig J. Thomas | J. Logue | R. S. Bennett | Huanying Zhou | Ian Crozier | Craig Thomas | Judith M White | Richard S Bennett | J. Dyall | Huanying Zhou | M. Holbrook | J. Michelotti | Lisa M Johansen | Elizabeth A. Nelson | Pamela J Glass | James Logue | Brit J. Hart | Elizabeth A Nelson | Brit J Hart | Walter M Vargas | Robin Gross | Julia Michelotti | Nicole Deiuliis | Patrick J Morris | Gene G Olinger | J. White | R. Gross | Crystal McKnight | Tim Mierzwa | Carleen Klumpp-Thomas | Nicole M Deiuliis | James Logue
[1] J. Dye,et al. Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects , 2017, The Journal of clinical investigation.
[2] G. Kobinger,et al. A Rapid Screening Assay Identifies Monotherapy with Interferon-ß and Combination Therapies with Nucleoside Analogs as Effective Inhibitors of Ebola Virus , 2016, PLoS neglected tropical diseases.
[3] Berenbaum Mc. What is synergy? , 1989, Pharmacological reviews.
[4] A. Azman,et al. Effect of Artesunate-Amodiaquine on Mortality Related to Ebola Virus Disease. , 2016, The New England journal of medicine.
[5] J. Manno,et al. Toxicology of ipecac: a review. , 1977, Clinical toxicology.
[6] P. Formenty,et al. Ebola RNA Persistence in Semen of Ebola Virus Disease Survivors — Final Report , 2017, The New England journal of medicine.
[7] Michael A Proschan,et al. A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. , 2016, The New England journal of medicine.
[8] J. Loureiro,et al. PIKfyve, a Class III Lipid Kinase, Is Required for TLR-Induced Type I IFN Production via Modulation of ATF3 , 2014, The Journal of Immunology.
[9] P. Shinn,et al. Synergistic drug combination effectively blocks Ebola virus infection , 2017, Antiviral research.
[10] Joshua C. Johnson,et al. Evaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus , 2016, PloS one.
[11] Thi Huyen Tram Nguyen,et al. Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted , 2017, PLoS neglected tropical diseases.
[12] Michael Costanzo,et al. Systematic exploration of synergistic drug pairs , 2011, Molecular systems biology.
[13] Thi Huyen Tram Nguyen,et al. Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques , 2018, PLoS medicine.
[14] Jia-Fu Jiang,et al. Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated With Favipiravir (T-705)-Sierra Leone, 2014. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] H. Feldmann,et al. Post-exposure treatments for Ebola and Marburg virus infections , 2018, Nature Reviews Drug Discovery.
[16] John-Arne Røttingen,et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!) , 2017, The Lancet.
[17] I. D. Manger,et al. A Systematic Screen of FDA-Approved Drugs for Inhibitors of Biological Threat Agents , 2013, PloS one.
[18] H. Ebihara,et al. A Novel Life Cycle Modeling System for Ebola Virus Shows a Genome Length-Dependent Role of VP24 in Virus Infectivity , 2014, Journal of Virology.
[19] Lisa E. Hensley,et al. A screen of approved drugs and molecular probes identifies therapeutics with anti–Ebola virus activity , 2015, Science Translational Medicine.
[20] H. Feldmann,et al. Lack of Protection Against Ebola Virus from Chloroquine in Mice and Hamsters , 2015, Emerging infectious diseases.
[21] S. Bavari,et al. Discovering Drugs for the Treatment of Ebola Virus , 2017, Current Treatment Options in Infectious Diseases.
[22] Justine R. Smith,et al. Persistence of Ebola Virus in Ocular Fluid during Convalescence. , 2015, The New England journal of medicine.
[23] Kathryn L. Schornberg,et al. Multiple Cationic Amphiphiles Induce a Niemann-Pick C Phenotype and Inhibit Ebola Virus Entry and Infection , 2013, PloS one.
[24] D. Stuart,et al. Target Identification and Mode of Action of Four Chemically Divergent Drugs against Ebolavirus Infection , 2017, Journal of medicinal chemistry.
[25] Y. Sakurai,et al. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment , 2015, Science.
[26] E. Nelson,et al. Clomiphene and Its Isomers Block Ebola Virus Particle Entry and Infection with Similar Potency: Potential Therapeutic Implications , 2016, Viruses.
[27] D. Stuart,et al. Toremifene interacts with and destabilizes the Ebola virus glycoprotein , 2016, Nature.
[28] M. Prichard,et al. A three-dimensional model to analyze drug-drug interactions. , 1990, Antiviral research.
[29] J. Dye,et al. Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability , 2017, Cell.
[30] W. Greco,et al. The search for synergy: a critical review from a response surface perspective. , 1995, Pharmacological reviews.
[31] Dafna M. Abelson,et al. Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses , 2017, Cell.
[32] Paul Shinn,et al. Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs , 2014, Emerging Microbes & Infections.
[33] J. Lehár,et al. Synergistic drug combinations improve therapeutic selectivity , 2009, Nature Biotechnology.
[34] M. Berenbaum. What is synergy? , 1989, Pharmacological reviews.